ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

By: American College of Cardiology
Listen for free

  • Summary

  • The American College of Cardiology offers select interviews and summaries of cardiology’s most interesting research areas from ACCEL’s renowned library, hosted by ACCEL Editor-in-Chief Alison L. Bailey, MD, FACC, FAACPVR.
    American College of Cardiology Foundation. All rights reserved.
    Show more Show less
Episodes
  • Percutaneous Repair of Moderate-to-Severe or Severe Functional Mitral Regurgitation in Symptomatic Heart Failure Patients: RESHAPE-HF2 Trial

    Percutaneous Repair of Moderate-to-Severe or Severe Functional Mitral Regurgitation in Symptomatic Heart Failure Patients: RESHAPE-HF2 Trial
    Sep 24 2024
    The RESHAPE-HF2 (Randomized Investigation of the MitraClip Device in Heart Failure [HF]: Second Trial in Patients With Clinically Significant Functional Mitral Regurgitation [MR]) trial assessed the safety and efficacy of mitral transcatheter edge-to-edge repair (M-TEER) using MitraClip among symptomatic HF patients with secondary MR. The results of this trial indicate that M-TEER using the MitraClip on a background of maximally tolerated guideline-directed medical therapy (GDMT) was superior to GDMT alone in reducing HF hospitalization and mortality at 2 years in symptomatic HF patients with grade 3-4+ MR. In this interview, Drs. Sidney Smith and Stefan Anker discuss the benefits of RESHAPE-HF2, including reduction in HF hospitalization (particularly among those with a history of HF hospitalization within the past year), significant quality-of-life improvements, and other patient-centered outcomes. References: Anker SD, Friede T, von Bardeleben RS, et al., for the RESHAPE-HF2 Investigators. Transcatheter Valve Repair in Heart Failure With Moderate to Severe Mitral Regurgitation. N Engl J Med 2024;Aug 31:[Epub ahead of print]. Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
    Show more Show less
    13 mins
  • Beta Blocker Interruption in Patients With Prior MI: ABYSS Trial Results

    Beta Blocker Interruption in Patients With Prior MI: ABYSS Trial Results
    Sep 17 2024
    The goal of the ABYSS (Assessment of Beta-Blocker Interruption 1 Year After an Uncomplicated Myocardial Infarction on Safety and Symptomatic Cardiac Events Requiring Hospitalization) trial was to evaluate beta-blocker interruption compared with beta-blocker continuation after an uncomplicated myocardial infarction (MI). Although the efficacy of beta blockers on decreasing mortality has diminished in the reperfusion era in patients without heart failure, this class of well tolerated drugs remain useful to decrease the rate of rehospitalization in patients who have suffered MI. In this interview, Drs. Deepak Bhatt and Johanne Silvain discuss the results of ABYSS and beta blocker interruption in patients with prior MI. References: Silvain J, Cayla G, Ferrari E, et al., for the ABYSS Investigators of the ACTION Study Group. Beta-Blocker Interruption or Continuation After Myocardial Infarction. N Engl J Med 2024;Aug 30:[Epub ahead of print]. Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
    Show more Show less
    12 mins
  • Dr. Jim Januzzi talks with Guideline Author Dr. Lynne Stevenson About "Heart Failure" and "Heart Success"

    Dr. Jim Januzzi talks with Guideline Author Dr. Lynne Stevenson About "Heart Failure" and "Heart Success"
    Sep 10 2024

    It is imperative that clinicians understand the differences in each patient and how effective therapies must be individualized and often combined to treat patients with varying profiles. Efforts to unify heart failure across the ejection fraction and rebrand "heart failure" to "heart success" may be achieved by better understanding patients to prevent progression to stage C or D.

    In this episode, Dr. Jim Januzzi interviews guideline author Dr. Lynne Stevenson on the importance of understanding the optimal evaluation and management of patients with heart failure.

    This podcast is part of the Heart Failure & SGLT2is: The New Pillar in Care grant initiative.

    Show more Show less
    11 mins
Physical Illness & Disease Hygiene & Healthy Living
Show more Show less

What listeners say about ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available